Ingredient Guide
NAD+ (Nicotinamide): Benefits, Dosage, and What the Research Says
Inside every cell, NAD+ powers energy production and DNA repair. Here is what human research actually shows about supplementing its precursors.
Written by Jessica Medson
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell that is essential for energy metabolism, DNA repair, and the activity of longevity-linked enzymes called sirtuins. Because oral NAD+ itself is poorly absorbed, supplements deliver precursor molecules -- primarily nicotinamide (a form of vitamin B3), nicotinamide mononucleotide (NMN), or nicotinamide riboside (NR) -- which the body converts into NAD+. Human clinical trials demonstrate that these precursors can increase blood NAD+ levels by 40-142% at doses of 250-1000 mg/day, with early evidence suggesting modest benefits for physical performance and insulin sensitivity in older or metabolically compromised adults; however, large confirmatory trials are still ongoing and overall evidence remains preliminary.
What Is NAD+ (Nicotinamide)?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It participates in hundreds of biochemical reactions, most critically the conversion of nutrients into cellular energy (ATP) through glycolysis, the citric acid cycle, and oxidative phosphorylation. It also serves as a substrate for enzymes involved in DNA repair and gene expression regulation.1
Despite widespread marketing, oral NAD+ itself is largely degraded before reaching cells. The molecule is too large and charged to cross most cell membranes in meaningful quantities. Instead, the body synthesizes NAD+ from smaller precursor molecules through the salvage biosynthesis pathway:
- Nicotinamide (NAM) -- a form of vitamin B3 (also called niacinamide) and the simplest, most abundant dietary NAD+ precursor
- Nicotinamide riboside (NR) -- a nucleoside form of vitamin B3 that sits one enzymatic step closer to NAD+
- Nicotinamide mononucleotide (NMN) -- the most direct precursor, one phosphorylation step from NAD+
NMN and NR are the forms most studied in recent human clinical trials and are the active ingredients in most commercially labeled "NAD+ supplements." Products marketed simply as "NAD+" or "nicotinamide" typically deliver one or more of these precursor forms.
Research in human tissues and animal models consistently shows that NAD+ concentrations decline with advancing age across multiple tissue types including skeletal muscle, skin, liver, and brain. This age-related decline is both a consequence of cellular aging processes and is thought to contribute to reduced mitochondrial efficiency and impaired DNA repair capacity.1 Restoring NAD+ levels through precursor supplementation is the core hypothesis driving this research area.
How Does NAD+ Work? The Mechanisms
NAD+ serves two distinct biochemical roles that are both relevant to health and aging:
1. Redox carrier for energy production
In its oxidized form (NAD+), the coenzyme accepts electrons from fuel molecules during cellular respiration, becoming NADH. NADH then donates electrons to the mitochondrial electron transport chain to drive ATP synthesis. This process underlies virtually all aerobic energy production in the body. When NAD+ availability falls, mitochondrial efficiency is compromised.
2. Substrate for NAD+-consuming signaling enzymes
Several enzyme families use NAD+ not as a carrier but as a consumable substrate, splitting the molecule as part of their catalytic cycle. These include:1
- Sirtuins (SIRT1-SIRT7) -- a family of NAD+-dependent deacetylases that regulate gene expression, circadian rhythm, mitochondrial biogenesis, and inflammation. Sirtuin activity falls when NAD+ is depleted, and rising NAD+ levels restore it.
- PARPs (poly-ADP-ribose polymerases) -- enzymes activated by DNA strand breaks that consume large amounts of NAD+ to add ADP-ribose chains to damaged DNA. Because oxidative stress and DNA damage accumulate with age, PARP activation increases and competes with sirtuins for available NAD+.
- CD38 -- an ectoenzyme and the dominant NAD+-consuming enzyme in many tissues, whose expression increases with age and chronic inflammation, further depleting NAD+ pools.
Supplementing NAD+ precursors is hypothesized to replenish NAD+ pools, restore sirtuin and PARP activity, and thereby support the cellular processes that these enzymes regulate. In a 12-week randomized trial, oral NMN (250 mg/day) in healthy men aged 65 or older significantly increased blood NAD+ and NAD+ metabolite concentrations, confirming that the precursor-to-NAD+ conversion occurs in humans at modest doses.7
Physical Performance and Muscle Function
Age-related muscle decline (sarcopenia) and reduced exercise capacity are among the most studied targets for NAD+ precursor supplementation, driven by the central role of NAD+ in mitochondrial energy production.
What the research shows
A 2022 randomized, double-blind, placebo-controlled trial enrolled 42 healthy men aged 65 and older and assigned them to either 250 mg/day of NMN or placebo for 12 weeks. NMN significantly elevated blood NAD+ and NAD+ metabolite concentrations. Among the functional outcomes assessed, gait speed and left grip strength showed nominally significant improvements in the NMN group; however, skeletal muscle mass did not change significantly.7 The researchers noted the intervention was well tolerated with no clinically significant adverse effects.
A 2021 randomized, double-blind study tested NMN supplementation (at 300, 600, or 1200 mg/day) in 48 recreationally trained amateur runners over 6 weeks of combined aerobic training. The medium and high NMN doses produced dose-dependent improvements in ventilatory thresholds (VO2 at VT1 and VT2) compared to placebo. Maximum oxygen uptake (VO2max) did not change significantly, suggesting the benefit may relate more to oxygen utilization efficiency in skeletal muscle than to cardiac output.6
A 2024 systematic review of 10 RCTs encompassing 437 participants (mean age 58 years, mean follow-up 9.6 weeks) examined the effects of NMN supplementation on physical performance parameters. Average grip strength increased from 29.9 kg to 30.5 kg pre- to post-intervention, and NMN was well tolerated across all trials. The review concluded that improvements were present but non-significant at the aggregate level, partly due to heterogeneity in outcome measures and study populations.12
What this means for you: Research suggests NAD+ precursor supplementation may help maintain walking speed and exercise efficiency in middle-aged and older adults, particularly when combined with physical activity. Effects are modest and evidence is preliminary. These findings should not be interpreted as claims that NAD+ builds muscle or replaces structured exercise.
Metabolic Health and Insulin Sensitivity
NAD+ plays a role in glucose metabolism through its involvement in mitochondrial function and through sirtuins that regulate insulin signaling pathways. Several human trials have examined whether boosting NAD+ via NMN supplementation supports blood sugar regulation.
What the research shows
One of the most rigorous human trials was a 10-week randomized, placebo-controlled study published in Science in 2021. Twenty-five postmenopausal women with prediabetes who were overweight or obese received 250 mg/day of NMN. NMN significantly increased insulin-stimulated glucose disposal compared to placebo and enhanced skeletal muscle insulin signaling, as evidenced by increased phosphorylation of AKT and mTOR proteins in muscle biopsies. Gene expression in muscle also shifted toward pathways involved in tissue remodeling.5
However, a 2024 systematic review and meta-analysis that pooled 8 RCTs (342 adults, NMN doses 250-2000 mg/day for 14 days to 12 weeks) found no statistically significant improvements in fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profiles. The authors noted that participants were predominantly non-diabetic, relatively healthy adults -- a population where baseline metabolic function may leave less room for measurable improvement.13
What this means for you: Preclinical data suggest NAD+ supports metabolic function, and one well-designed human trial found improved insulin sensitivity specifically in women with prediabetes. In generally healthy adults, metabolic benefits from NMN supplementation have not been demonstrated consistently in aggregate analyses. Research is still evolving in this area.
Cardiovascular Health: Blood Pressure and Arterial Stiffness
Arterial stiffness and rising blood pressure with age are linked to oxidative stress and reduced nitric oxide availability -- processes that NAD+-dependent sirtuins and PARP enzymes may influence. A small body of human pilot data has examined whether NR supplementation can support vascular health.
What the research shows
A 2018 double-blind, randomized crossover trial enrolled 24 healthy adults aged 55-79 and tested 1000 mg/day of NR for 6 weeks against placebo. NR increased blood cellular NAD+ by approximately 60% compared to placebo. In participants with elevated baseline systolic blood pressure, NR was associated with a trend toward a 9 mmHg reduction in systolic blood pressure and reduced aortic stiffness (lower carotid-femoral pulse wave velocity). These cardiovascular trends did not reach statistical significance in the full group.2
Separately, a 2017 randomized, double-blind, placebo-controlled trial in 120 healthy adults aged 60-80 found that 8 weeks of NR combined with pterostilbene (a polyphenol) raised blood NAD+ by approximately 40% at standard dose and 90% at double dose. The double-dose group showed improved scores on mobility tests (chair stand and 6-minute walk), and no serious adverse events were reported across groups.3
Based on these pilot findings, a phase IIa randomized controlled trial protocol was published in 2022 to formally test NR at 500 mg twice daily for 3 months in 94 adults with above-normal systolic blood pressure (120-159 mmHg). Full efficacy results from this confirmatory trial are awaited.9
What this means for you: Preliminary human data suggest NAD+ precursor supplementation may support healthy vascular function in older adults, particularly those with above-normal blood pressure at baseline. These findings are pilot-level and do not constitute evidence that NAD+ supplements lower blood pressure as a clinical intervention.
Safety, Side Effects, and Drug Interactions
General safety profile
NAD+ precursor supplements have a favorable short-term safety record across multiple human trials. A safety evaluation of 1250 mg/day of NMN for 4 weeks in 31 healthy adults (ages 20-65) found no clinically significant changes in blood chemistry, hematological markers, or urinalysis. Mild events (loose stool, acne, common cold, temporary blood pressure elevation) were reported in five participants but were judged by investigators not to be causally linked to NMN.8
A dose-ranging 8-week trial of 100-1000 mg/day NR in 140 overweight adults found no significant differences in adverse events between active and placebo groups, no flushing (unlike niacin/nicotinic acid), and no increases in LDL cholesterol or plasma homocysteine at any dose.4
At the high end, the NR-SAFE trial tested 3000 mg/day NR for 4 weeks in 20 Parkinson's disease patients. No moderate or severe adverse events occurred. A mild, transient rise in serum homocysteine was observed early in treatment but stabilized without depleting methyl donor reserves (folate, B12).11
Key cautions
- Long-term safety is unestablished: Nearly all human trials lasted 4-12 weeks. Safety at typical supplement doses beyond 3 months has not been evaluated in controlled studies.
- Pregnancy and breastfeeding: No safety data exist for pregnancy or lactation. Avoid supplementation unless directed by a licensed healthcare provider.
- Diabetes medications: Nicotinamide can affect insulin secretion and blood glucose at high doses. Individuals taking diabetes medications (metformin, insulin, sulfonylureas) should consult a physician before use.
- High-dose nicotinamide: Unlike niacin (nicotinic acid), nicotinamide does not cause skin flushing. However, at very high doses (above 3 g/day), nausea, liver enzyme elevation, and headache have been reported. Standard supplement doses (250-500 mg) are well below this threshold.
- Cancer treatment: NAD+ metabolism is a therapeutic target in certain cancer therapies. Patients receiving oncology treatment should consult their oncologist before using any NAD+ precursor supplement.
- Methyl donor depletion: High-dose NAD+ precursor supplementation increases demand on methyl donor pathways. Adequate intake of folate, vitamin B12, and choline is advisable. Monitoring homocysteine levels may be appropriate with long-term high-dose use.
- Drug interactions: Theoretical interactions exist with anticoagulants and immunosuppressants. Consult a pharmacist or physician before combining with prescription medications.
This information is educational and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen, especially if you have a medical condition or take prescription medications.
NAD+ Precursor Dosage: What Human Trials Used
No official recommended dietary allowance (RDA) exists for NMN or NR as isolated supplements. The following doses reflect what has been studied in published human clinical trials. Start at the lower end and consult a healthcare provider.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| General NAD+ support (NMN) | 250-500 mg NMN daily | Morning, with or without food | 250 mg/day was the dose in the Igarashi et al. 2022 RCT in older men; elevated blood NAD+ significantly within 12 weeks |
| General NAD+ support (NR) | 250-500 mg NR daily | Morning, with or without food | Conze et al. 2019 found 300 mg NR raised blood NAD+ by 51% and 1000 mg raised it by 142% over 8 weeks in overweight adults |
| Exercise performance support (NMN) | 600-1200 mg NMN daily | Before or with exercise | Dose range from Liao et al. 2021 trial in recreational runners; higher doses produced greater ventilatory threshold improvements |
| Cardiovascular support (NR, pilot data) | 500 mg NR twice daily (1000 mg/day total) | Morning and evening | Dose used in Martens et al. 2018 crossover trial; raised blood NAD+ ~60% and showed blood pressure trends in older adults |
| Short-term safety upper limit studied | 1250 mg NMN or 3000 mg NR daily | As studied in respective trials | Both doses were found safe in 4-week trials; NOT recommended for routine supplementation without medical supervision |
Doses above 500 mg/day have not been studied long-term. Most supplements provide 250-500 mg per serving. NMN and NR are not interchangeable on a mg-for-mg basis due to differences in bioavailability and metabolic conversion rates.
What the Evidence Shows at a Glance
Summary of outcomes studied in human clinical trials of NAD+ precursor supplementation (NMN and NR). Evidence tier reflects study quality and consistency of findings.
| Outcome | What Studies Show | Population Studied | Evidence Tier |
|---|---|---|---|
| Blood NAD+ elevation | NR 100-1000 mg/day raises blood NAD+ 22-142% within 2 weeks; NMN 250 mg/day raises it 1.7-2.6x in 12 weeks | Healthy overweight and older adults | Tier A -- multiple RCTs, consistent |
| Physical performance (gait, grip) | NMN 250 mg/day improved gait speed and grip strength nominally in older men; aggregate systematic review showed non-significant improvements | Adults 58-65+ years | Tier A -- small RCTs, modest, mixed |
| Exercise / aerobic capacity | NMN 600-1200 mg/day improved ventilatory thresholds in recreational runners; VO2max unchanged | Recreationally trained adults | Tier A -- single RCT |
| Insulin sensitivity | NMN 250 mg/day significantly improved insulin-stimulated glucose disposal in prediabetic women; no effect in meta-analysis of mainly healthy adults | Postmenopausal women with prediabetes; also healthy adults | Tier A -- mixed (population-dependent) |
| Blood pressure / arterial stiffness | NR 1000 mg/day showed -9 mmHg systolic blood pressure trend in older adults with elevated baseline; confirmatory trial results pending | Adults 55-79 with elevated baseline BP | Tier A -- pilot only, not confirmed |
| Neurological symptoms (Parkinson's) | NR 3000 mg/day for 4 weeks was safe and associated with motor improvement signal | Parkinson's disease patients | Tier A -- phase I trial, preliminary |
| Longevity / lifespan extension | No human evidence available; robust preclinical data in animal models only | Animal models only | Tier C -- human evidence not established |
Tier A = human RCT or meta-analysis; Tier B = human observational; Tier C = animal or cell studies only. Small sample sizes and short durations limit confidence in Tier A findings here.
Frequently Asked Questions
What is NAD+ (Nicotinamide) good for?
NAD+ is a coenzyme that powers cellular energy production and supports DNA-repair enzymes called sirtuins and PARPs. Research suggests NAD+ precursor supplements (NMN and NR) may help maintain physical performance, support insulin sensitivity in people with prediabetes, and contribute to vascular health in older adults. Evidence is early-stage; no approved therapeutic claims exist.
What is the difference between NAD+, NMN, and nicotinamide riboside (NR)?
NAD+ is the active coenzyme inside cells. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursor molecules the body converts into NAD+. Nicotinamide (a form of vitamin B3) is the simplest precursor. Oral NAD+ itself is poorly absorbed, which is why supplements deliver NMN or NR instead. Both have been shown in human trials to reliably raise blood NAD+ levels.
How much NAD+ (Nicotinamide) should I take per day?
Human trials showing blood NAD+ increases typically used 250-500 mg/day of NMN or NR. A 2019 RCT found 300 mg/day NR raised blood NAD+ by 51% and 1000 mg/day raised it by 142%. There is no established recommended daily intake. Most supplement labels suggest 250-500 mg; consult a healthcare provider before exceeding this range.
Does NAD+ supplementation help with energy levels?
No large-scale human trial has directly measured subjective energy levels as a primary endpoint. NAD+ is essential for mitochondrial energy production, and declining NAD+ with age is linked to reduced cellular energy metabolism. Preclinical evidence is strong, but controlled human evidence for an energy benefit in healthy adults is not yet established.
Is NAD+ (Nicotinamide) safe to take daily?
Short-term human trials up to 12 weeks at doses of 250-1250 mg/day NMN and 1000-3000 mg/day NR have found no serious adverse events. Nicotinamide does not cause the skin flushing associated with niacin. Long-term safety beyond 3 months has not been studied in controlled trials. Pregnancy, breastfeeding, and concurrent cancer treatment are situations requiring medical guidance.
Does NAD+ (Nicotinamide) slow aging or extend lifespan?
There is no human evidence that NAD+ supplementation extends lifespan. Animal studies show impressive longevity effects when NAD+ levels are restored, but these have not been replicated in human trials. What human trials have shown is that NAD+ precursors can support specific physiological functions that decline with age, such as muscle performance and insulin sensitivity, in limited populations.
Can NAD+ (Nicotinamide) lower blood pressure?
A 2018 pilot crossover trial in 24 older adults found NR at 1000 mg/day was associated with a trend toward 9 mmHg lower systolic blood pressure in those with elevated baseline readings. This pilot finding has not yet been confirmed in a larger RCT. NAD+ supplements should not be used as a substitute for prescribed blood pressure medications.
What are the side effects of NAD+ (Nicotinamide) supplements?
In published human trials, NMN and NR have been well-tolerated with no consistent pattern of adverse effects at standard doses (250-1000 mg/day). Mild and transient reports across trials include loose stools, nausea at high doses, and a brief rise in homocysteine with very high NR doses. Unlike niacin, nicotinamide does not cause flushing. Report any adverse effects to your healthcare provider.
When is the best time to take NAD+ (Nicotinamide)?
Most clinical trials administered NMN or NR once daily in the morning, with or without food. No trial has directly compared morning versus evening dosing on outcomes. Given NAD+ involvement in circadian rhythm regulation via sirtuins, morning timing is a reasonable default choice, but evidence to support a specific timing recommendation is lacking.
Does NAD+ (Nicotinamide) help with muscle building or sports performance?
Human evidence does not support NAD+ supplementation for muscle hypertrophy. A 2022 RCT in older men showed improved gait speed and grip strength but no change in muscle mass with NMN 250 mg/day. A 2021 RCT found NMN improved ventilatory efficiency in recreational runners but not VO2max. These findings suggest support for functional performance rather than muscle-building effects.
Shop NAD+ (Nicotinamide)
HealthFare NAD+ (Nicotinamide) supplements
Scientific References
- 1.Imai S, Guarente L NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014. PubMed: 24786309Preclinical (animal / cell)
- 2.Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. PubMed: 29599478Clinical (RCT / meta-analysis)
- 3.Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging and Mechanisms of Disease. 2017. PubMed: 29184669Clinical (RCT / meta-analysis)
- 4.Conze D, Brenner C, Kruger CL Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. 2019. PubMed: 31278280Clinical (RCT / meta-analysis)
- 5.Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed: 33888596Clinical (RCT / meta-analysis)
- 6.Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021. PubMed: 34238308Clinical (RCT / meta-analysis)
- 7.Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022. PubMed: 35927255Clinical (RCT / meta-analysis)
- 8.Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific Reports. 2022. PubMed: 36002548Clinical (RCT / meta-analysis)
- 9.Freeberg KA, Craighead DH, Martens CR, You Z, Chonchol M, Seals DR Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Frontiers in Cardiovascular Medicine. 2022. PubMed: 35620522Clinical (RCT / meta-analysis)
- 10.Song Q, Zhou X, Xu K, Liu S, Zhu X, Yang J The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Advances in Nutrition. 2023. PubMed: 37619764Human observational
- 11.Berven H, Kverneng S, Sheard E, Sognen M, Af Geijerstam SA, Haugarvoll K, Skeie GO, Dolle C, Tzoulis C NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature Communications. 2023. PubMed: 38016950Clinical (RCT / meta-analysis)
- 12.Wen J, Syed B, Kim S, Shehabat M, Ansari U, Razick DI, Akhtar M, Pai D Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. Cureus. 2024. PubMed: 39221308Clinical (RCT / meta-analysis)
- 13.Chen F, Zhou D, Kong APS, Yim NT, Dai S, Chen YN, Hui LL Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports. 2024. PubMed: 39531138Clinical (RCT / meta-analysis)